What do systematic reviews say?

Metronidazole vs placebo

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1964 participants
  Moderate

Metronidazole vs placebo

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 514 participants
  High

Metronidazole vs placebo

Metronidazole probably leads to lower duration of remission compared with placebo (moderate certainty).

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  RR 0.5 [0.25, 0.99]
  1 study · 88 participants
  Moderate

Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel

The review found no eligible studies for this question.

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel

The review found no eligible studies for this question.

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel

Doxycycline 40 mg + metronidazole 1% gel may leads to lower proportion of participants with adverse event compared with doxycycline 100 mg + metronidazole 1% gel (low certainty).

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  RR 0.25 [0.11, 0.54]
  1 study · 91 participants
  Low

Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Low

Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Low

Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Low

Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Low

Doxycycline 40 mg + metronidazole 1% gel vs doxycycline 100 mg + metronidazole 1% gel

The review found no eligible studies for this question.

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Metronidazole + SRP vs SRP

It is very uncertain whether metronidazole + SRP changes probing pocket depth compared with SRP (very low certainty).

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  MD -1.11 [-2.84, 0.61]
  2 studies · 47 participants
  Very low
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Intermediate-term (> 3 months to < 1 year)
  MD -0.59 [-0.95, -0.23]
  4 studies · 94 participants
  GRADE not reported
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD -0.10 [-0.37, 0.16]
  4 studies · 108 participants
  GRADE not reported

Metronidazole + SRP vs SRP

It is very uncertain whether metronidazole + SRP changes percentage of bleeding on probing (BOP) compared with SRP (very low certainty).

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  MD -6.90 [-22.10, 8.30]
  1 study · 22 participants
  Very low
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD -9.00 [-16.59, -1.40]
  4 studies · 108 participants
  GRADE not reported
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Intermediate-term (> 3 months to < 1 year)
  MD -4.62 [-18.83, 9.58]
  2 studies · 45 participants
  GRADE not reported

Metronidazole + SRP vs SRP

It is very uncertain whether metronidazole + SRP changes percentage of closed pockets compared with SRP (very low certainty).

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  MD -12.20 [-29.23, 4.83]
  1 study · 22 participants
  Very low
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Intermediate-term (> 3 months to < 1 year)
  MD -7.00 [-23.57, 9.57]
  1 study · 22 participants
  GRADE not reported
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD -2.56 [-12.33, 7.22]
  2 studies · 51 participants
  GRADE not reported

Metronidazole + SRP vs SRP

It is very uncertain whether metronidazole + SRP changes adverse events compared with SRP (very low certainty).

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  No severe adverse effects were reported by any of the participants in 1 study. 2 studies have not reported adverse events.
  3 studies · 71 participants
  Very low

Metronidazole + SRP vs SRP

Metronidazole + SRP showed no clear difference in clinical attachment level (CAL) compared with SRP; GRADE not reported.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Short-term (≤ 3 months)
  MD 0.04 [-0.43, 0.50]
  4 studies · 108 participants
  GRADE not reported
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  MD -1.12 [-2.24, 0.00]
  3 studies · 71 participants
  Very low
• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Intermediate-term (> 3 months to < 1 year)
  MD -0.49 [-1.29, 0.31]
  4 studies · 94 participants
  GRADE not reported

Metronidazole + SRP vs SRP

The review found no eligible studies for this question.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  Included studies have not reported this outcome
  Studies not reported
  No studies found

Metronidazole + SRP vs SRP

The review found no eligible studies for this question.

• Adjunctive systemic antimicrobials for the non‐surgical treatment of periodontitis 2020 · Cochrane All outcomes

  Long-term (≥ 1 year)
  Included studies have not reported this outcome
  Studies not reported
  No studies found

Topical metronidazole vs oral (oxy)tetracycline

The review found no eligible studies for this question.

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical metronidazole vs oral (oxy)tetracycline

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 182 participants
  Moderate